Industry Trends

Hari Pujar, chief technology officer of Spark Therapeutics, discusses the unique manufacturing and scale-up challenges involved with cell and gene therapy production.

Pharrm Exec's 2020 Pipeline Report

As the microbiome "moves into the mainstream," Pharm Exec looks at how industry activity in the space is heating up.

Healthy companies with coherent integration strategies will benefit from applying six lessons to ensure successful integration, writes Mark Bouch.

As payers increasingly stifle new drug launches, investors in biopharmaceutical companies pursue better sources of insights.

Pharm Exec’s latest analysis of financial performance reveals that it’s those drugmakers maximizing the difference between the value and the cost of their capital investments that are delivering the most bang for the buck to shareholders.

As well as official European projections of sharply slowing industry growth and geopolitical concerns, pharma executives face additional hazards as they plot their medium-term strategies, writes Reflector.

Clive Glover and Mark Szczypka discuss the complexities of scaling up the manufacturing of gene therapies and gene-modified cell therapies to industrial levels.

The US could theoretically treat every single American living with HIV without spending an extra dollar on drugs. And President Trump can broker a deal to do it, write Anil Soni and Ya’ir Aizenman.

A 2019 study reveals further marginal decline in the pharma industry's reputation. Sven Klingemann suggests some "recovery solutions".

Our 19th annual listing reveals some interesting maneuvering of ranks, as companies focus on diversification, big-brand expansions, and positioning a new wave of products to compete in an advancing but complex future treatment market.

While culture may "eat" strategy, shared understanding creates both culture and strategy, write Steve Figman and Sean Robertson.

The opioid crisis dominated the news in this year’s annual audit of press coverage of the pharmaceutical industry. Stephen J. Porth and George P. Sillup report.

The World Health Assembly's new resolution on transparency in the market for health-related products is weaker than the original draft but still contains measures that could have a substantial impact on market access around the world, writes Neil Grubert.

Findings support the belief that today’s pharma finance teams should be engaged across all functional areas, including regulatory, supply chain, manufacturing, and commercial. What does that mean for current and future CFOs in the industry?

The outlook for pharma M&A continues to be strong, writes Michael Jewell.

Stefan Spazek outlines the steps for biopharma startups in tapping non-dilutive financing options.

While gene therapies and cellular treatments are a boon for patients, they can be a financial bane for payers. Jane Barlow, Russell Teagarden, and Mark Trusheim outline alternative financing approaches, customizable for each payer’s needs and for each therapy’s characteristics.

Pharm Exec’s annual look at what lies ahead for the biopharma industry in the coming months examines eight key trends that are seemingly at tipping points in their evolution and poised to shape the life sciences landscape in 2019.

Highlighting a few topics that just missed the cut for our annual Industry Outlook-but are worth keeping a close eye on.

The increase in new drug approvals and candidates in development are good signs for pharma and biotech, but both sectors face continued pricing, cost, and healthcare policy-related challenges ahead.

Efforts intensify to bring outlays more in line with global trends.

A growing range of MBAs with concentrations in pharmaceuticals and healthcare management are on offer. Pharm Exec look at how three of the top programs in the US prepare their students for industry success.

Pharm Exec’s latest company leaderboard in delivering shareholder value highlights the most critical measure of management performance-return on invested capital.

To succeed in developing targeted medicines, companies need a biomarker strategy and the expertise to make smart decisions about clinical trial design, assays, technology platforms and collaborative partners, write Barry S. Sall and Angela X. Qu.